Free Priority Shipping on USA orders over $150 – 24‑hr processing – Live phone support
Free Priority Shipping on USA orders over $150 – 24‑hr processing – Live phone support
$700.00
PT-141, also known as bremelanotide, is a synthetic heptapeptide that acts as a melanocortin receptor agonist and is widely studied for its role in central nervous system pathways linked to sexual arousal and desire. Unlike agents that primarily influence peripheral blood flow, PT-141 interacts with melanocortin receptors (notably MC4R) in the brain, making it a key focus of current research on neurogenic modulation of sexual function. Preclinical and clinical investigations have evaluated PT-141 as a potential option for conditions such as erectile dysfunction and hypoactive sexual desire disorder, highlighting its distinct mechanism of action versus traditional PDE5 inhibitors.
At Peak Science Peptides, PT-141 is offered strictly for laboratory and in vitro research purposes only, not for human use. All PT-141 supplied by Peak Science Peptides is pharmaceutical‑grade, produced under stringent quality standards, and supported by third‑party laboratory analysis to verify identity, purity, and potency prior to release. This focus on analytical confirmation is designed to support reproducible, publication‑quality research outcomes across academic, institutional, and commercial R&D settings. PT-141 is typically studied in peptide stability assays, receptor binding models, and mechanistic investigations of melanocortin signaling pathways.
Researchers value PT-141 for its well‑characterized structure, defined activity at melanocortin receptors, and growing body of peer‑reviewed data. Ongoing and past studies have explored dose–response relationships, pharmacokinetics, receptor selectivity, and safety profiles in controlled environments. When incorporated into rigorous experimental designs, PT-141 can help clarify how central melanocortin signaling contributes to complex behavioral and physiological endpoints relevant to sexual function research. Peak Science Peptides supports this work by providing consistent batches, detailed lot documentation, and third‑party test reports upon request.
In research models, PT-141 binds to melanocortin receptors in the central nervous system, increasing intracellular cAMP and activating downstream signaling cascades. This central activity distinguishes PT-141 from traditional vasodilator therapies by targeting neural circuits involved in libido and sexual motivation rather than solely peripheral vascular effects.
Published data indicate that PT-141 has been studied as a potential therapeutic candidate for erectile dysfunction in men and hypoactive sexual desire disorder or related arousal disorders in women. These investigations have included phase‑based clinical trials designed to assess efficacy, tolerability, and comparative performance versus existing treatments.
Bremelanotide has received regulatory approval in certain formulations for specific sexual desire disorders in women in some markets, but these approvals are tied to defined products, routes, and indications. PT-141 offered by research suppliers such as Peak Science Peptides is not a finished pharmaceutical product and is sold strictly for laboratory research only, with no claims of diagnosis, treatment, or cure.
Peak Science Peptides emphasizes that all peptides, including PT-141, are pharmaceutical‑grade and accompanied by independent third‑party laboratory testing to confirm purity, identity, and concentration. This quality framework helps reduce variability across experiments and supports robust, reproducible research outcomes in both academic and commercial laboratories.
Reviews
There are no reviews yet.